
    
      GSK1144814 is a dual neurokinin-1 (NK1) and neurokinin-3 (NK3) antagonist with the potential
      to treat schizophrenia & depression.

      This study described in the present protocol consists of two sections. Part A is the first
      administration into man to evaluate the safety, tolerability and pharmacokinetics of single
      ascending doses of GSK1144814. The study is a single-blind, randomised, placebo-controlled
      design in healthy male and female (of non-childbearing potential) subjects. Part B will be an
      open-label design in healthy male subjects to assess the GSK1144814 NK1 receptor occupancy by
      positron emission tomography (PET) scanning with [11C]-GR205171.
    
  